Skip to main
STAA
STAA logo

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 0%
Hold 46%
Sell 8%
Strong Sell 0%

Bulls say

Staar Surgical Co. is poised for sustained growth, with projected sales increasing from a normalized $146 million in 2025 to $156 million in 2026, reflecting a compound annual growth rate driven by market growth and gains in ICL market share. The company is expected to benefit from the anticipated domestic launch of the EVO lens and an increase in international adoption, which positions it for above-market volume growth and significant margin improvement. Additionally, the management's focus on streamlining operations and reducing costs further strengthens the company’s potential for long-term growth in the refractive surgery market.

Bears say

Staar Surgical Co. is facing significant challenges that contribute to a negative outlook on its stock, including flat to declining revenue projections primarily due to issues in the Chinese market and elevated inventory levels impacting sales recognition. The company's recent performance reflected a disappointing $27.5 million revenue hit, which compounded existing weaknesses and raised concerns about future guidance and normalized earnings. Additionally, various risks, such as patients' affordability of out-of-pocket expenses for procedures, competitive pressures from lower-cost alternatives, and geopolitical vulnerabilities, further exacerbate the uncertainty surrounding Staar Surgical's financial health.

STAAR Surgical (STAA) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 0% recommend Buy, 46% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 13 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.